Monday, October 15, 2018
 
 
Company News: Page (1) of 1 - 01/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
IBA SA : TRANSPARENCY NOTIFICATION

(January 12, 2018)

IBA - TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.

Reason for the notification Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Kempen Capital Management NV
Transaction date   01/01/2018
Threshold that is crossed (in %)   3%
Upwards crossing further to the acquisition of voting rights
Denominator   29 962 246
Voting rights (number)   900 174
Voting rights (%)   3,00%
Chain of control Van Lanschot Kempen N.V. < 100%> F. van Lanschot Banklers NV <100%> kempen & Co NV <100%> Kempen Capital Management NV. Kempen se réfère à la declaration d'indépendance (datée du 15 novembre 2017).
Additional information Kempen Capital Management NV appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com



For further information, please contact:

IBA

Stephanie Bauwin
Legal Counsel
+32 10 203 924
[email protected]

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/db35d873-23c8-457d-8a08-06c30d34761d


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Lee Health Selects GeBBS iCode Assurance SaaS Solution for HIM Auditing Workflow and Analytics
  • Global $6.87 Billion Contrast Agents/Media Market to 2025
  • Contrast Agents/Media Market, 2025
  • Global mHealth market is projected to attain a size of $132.2 billion by 2023
  • Biosurgery Market Analysis | Rising Investments in Healthcare and Expansions by Most Eminent Players Globally | Forecast 2023

    Cancer
  • Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
  • InSight Telepsychiatry Presents First Annual Partner Awards
  • Internet Brands' WebMD Acquires prIME Oncology
  • Global Next Generation Sequencing Market: Whole Genome Sequencing is Growing at the Fastest CAGR | Emerging Trends & Strategy Analysis, by Key Players; Illumina, Inc., Qiagen, Agilent Technologies, Ge
  • Connected Health Conference 2018 Keynote Series: FCC Chairman Ajit Pai, Champion Of Rural Broadband And Telehealth
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines